Medartis plans IPO to expand surgical implant business

Basel, Switzerland, where Medartis is based. (Switzerland Tourism)

Medartis is planning an IPO to bankroll the expansion of its internal surgical bone fixation business. The Swiss medical device manufacturer wants to list on its local exchange in the coming months.

Basel, Switzerland-based Medartis is a well-established private firm. Having begun life 20 years ago, the surgical implant specialist has grown into a profitable 480-person business with revenues north of $110 million. Now, Medartis thinks the time is right to inject more cash into its operation.

“The planned IPO will mark an important milestone in the development of Medartis and will allow us to take the company to the next level. There are numerous opportunities for us to grow, and the timing is right for us to offer shares and seek a listing, in order to be in a strong position to capture these favorable prospects,” Medartis founder and chairman Thomas Straumann said in a statement (PDF).


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Medartis established itself in the internal surgical bone fixation sector with a series of innovations, including a multidirectional locking system, a self-holding screw and a screw technology that ends the need for predrilling. The plan is to use the IPO money to introduce a string of new products over the next few years.

Management also sees the IPO haul benefiting existing products. Medartis already sells its devices in 44 countries but sees scope to gain ground in certain markets. The expansion of existing devices into additional indications is also on the cards.

Medartis hopes the mix of a solid platform, experienced management team and avenues for further growth will prove attractive to Swiss investors, who have been starved of new opportunities to back medical device companies in recent years. SFS, which has some involvement in medical components, went public in Switzerland in 2014 but overall it has been a quiet decade for Swiss device IPOs.

Suggested Articles

By employing heart rate signals, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu.

Nanox has raised $26 million to help fuel the development and commercialization of its "Star Trek"-inspired digital X-ray bed.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.